This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
EMD Millipore
other brands :
Oncogene Research Products, Calbiochem, Novagen, Merck, Upstate Biotechnology, Chemicon, LINCO, Novabiochem, Guava
product type :
antibody
product name :
phospho-EGFR (Tyr845) Antibody, clone 12A3
catalog :
04-283
quantity :
100 µg
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
12A3
The same clone is also sold as:
The same clone is also sold as:
- MyBioSource: MBS311323
- Enzo Life Sciences: BML-SA344-0050, BML-SA344-0010
- OriGene: AM00031PU-N, AM00031FC-N, AM00031BT-N
- BD Biosciences: 558381
- Santa Cruz Biotechnology: sc-57542
reactivity :
human, mouse
application :
western blot, ELISA, immunocytochemistry, immunoprecipitation
product information
Catalog Number :
04-283
Subcategory :
Cell Signaling
Product Name :
Anti-phospho-EGFR (Tyr845) Antibody, clone 12A3
Product Type :
Antibodies
Clonality :
Monoclonal Antibody
Gene ID :
P00533
Host Name :
Mouse
Antigen :
phospho-EGFR (Tyr845)
Clone :
12A3
Conjugate :
Purified
Isotype :
IgG1
Product Description :
Anti-phospho-EGFR (Tyr845) Antibody, clone 12A3
Cross Reactivity :
Human;Mouse
ALT Names :
ERBB; ERBB1
Immunogen :
KLH-conjugated synthetic peptide encompassing the surrounding amino acids of Tyr 845 in human EGFR.
Specificity :
Recognizes phosphorylated EGFR on Tyrosine 845.
Package Size :
100 µg
Uses :
ELISA;Immunocytochemistry;Immunoprecipitation;Western Blotting
Storage :
2 years at -20°C from date of shipment
company information
EMD Millipore
290 Concord Road
Billerica, Massachusetts 01821
Billerica, Massachusetts 01821
bioscienceshelp@emdchemical.com
https://www.emdmillipore.com888-854-3417
headquarters: United States
EMD Millipore is the Life Science division of Merck KGaA of Darmstadt, Germany
Hundreds of New Antibodies in the areas of:
View all the new antibodies at www.emdmillipore.com.
Hundreds of New Antibodies in the areas of:
|
|
questions and comments
